Comparison of Zuprevo™ (tildipirosin) and Draxxin® (tulathromycin) in the Control of BRD in Calf Ranch Cattle

Abstract
From September 2012, to March 1, 2013, a randomized clinical trial was conducted to determine the health performance differences between Zuprevo and Draxxin, both with a three-day PMI (post-metaphylactic interval).

Holstein heifers (n = 2,059) received their randomly allocated antibiotic (Zuprevo or Draxxin) after they left their hutch and prior to entering their randomly assigned pens. Resfl or Gold® (florfenicol and flunixin meglumine) was used to treat any animals identified as sick with BRD in the pens.

There was a statistical difference (p = 0.032) with regards to morbidity following the administration of the respective treatment groups’ antibiotic for the control of bovine respiratory disease (BRD). Ninety-five (8.46%) of the animals treated with Zuprevo (n = 1,030) broke with BRD compared to 128 (11.43%) of the animals treated with Draxxin (n = 1,029).

There were no statistically significant differences (p< 0.05) between the two treatment groups with regards to respiratory and depression scores, treatment success rates following treatment with Resfl Gold, mortality, chronicities and relapses.

This study demonstrated that Zuprevo was superior to Draxxin—with respect to morbidity rate—with both antibiotics having a three-day PMI, when used to control BRD in calves.

Objective
The purpose of this study was to determine the health performance of calf ranch cattle at high risk for developing BRD after the administration of one of the following antibiotics for the control of respiratory disease.

I. Zuprevo (tildipirosin)
II. Draxxin (tulathromycin)

Materials and Methods
Holstein heifers, weighing 165 to 240 lbs body weight (BW) and predicted to be at high-risk for bovine respiratory disease (BRD) received their randomly allocated antibiotic (Zuprevo or Draxxin, see below) for the control of respiratory disease after they left their hutch and prior to entering their randomly assigned pen, both of which occurred on the same day.

Treatment Groups
1. Zuprevo (tildipirosin): 4 mg/kg (1.0 mL/cwt), SQ in the neck one time with a three-day PMI (post-metaphylactic interval)
2. Draxxin (tulathromycin): 2.5 mg/kg (1.1 mL/cwt), SQ in the neck one time with a three-day PMI.

Animals were placed in equal sized pens, with two adjacent/paired pens per replicate with 22 replicates on test. Pen capacity was 55 animals/pen. There were 1,030 animals that received Zuprevo at enrollment and 1,029 head that received Draxxin at time of enrollment. The animals were then observed daily for clinical signs of respiratory disease. This trial began in late September 2012, and ended on March 1, 2013.

When an animal in either treatment group (Zuprevo or Draxxin) was identified as sick with BRD after its three-day PMI, it was treated with Resfl or Gold (40 mg/kg florfenicol, 2.2 mg/kg flunixin meglumine: 6 cc/cwt), SQ in the neck with a four-day PTI (post-treatment interval). Clinical signs used to diagnose BRD included nasal and ocular discharges, respiratory rate and character, presence and character of cough, demeanor (depression) and gauntness.

IMPORTANT SAFETY INFORMATION: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM. IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN. DO NOT USE Zuprevo™ 18% IN SWINE. Fatal adverse events have been reported following the use of tildipirosin in swine. NOT FOR USE IN CHICKENS OR TURKEYS. Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal. The effects Zuprevo™ 18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond slaughter withdrawal period.
Results and Discussion

There was a statistical difference (p = 0.032) with regards to morbidity following the administration of the respective treatment groups’ antibiotic for the control of BRD. Ninety-five (8.46%) of the animals treated with Zuprevo (n = 1,030) broke with BRD compared to 128 (11.43%) of the animals treated with Draxxin (n = 1,029). See Figure 1.

There were no statistically significant differences (p< 0.05) between the two treatment groups with regards to respiratory and depression scores, treatment success rates following treatment with Resflor Gold, mortality, chronics and relapses. See Table 1 for specific comparisons between treatment groups.

Conclusion

This study demonstrated that Zuprevo was superior to Draxxin, in morbidity rate, with both antibiotics having a three-day PMI, when used to control BRD in calves.

Following the administration of Zuprevo, only 8.46% (95/1,030) of the animals broke with BRD, which is statistically significant (p = 0.032) as compared to the 11.43% (128/1,029) of the animals that broke with BRD following the administration of Draxxin.

Figure 1. BRD Morbidity Following the Use of Zuprevo or Draxxin for the Control of BRD

Table 1. Variable Comparisons Between Zuprevo and Draxxin Treatment Groups

<table>
<thead>
<tr>
<th>Variable</th>
<th>Draxxin</th>
<th>Draxxin &quot;n&quot;</th>
<th>Zuprevo</th>
<th>Zuprevo &quot;n&quot;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enroll Temperature, F</td>
<td>102.2</td>
<td>1,029</td>
<td>102.2</td>
<td>1,030</td>
</tr>
<tr>
<td>Enroll Weight, lb.</td>
<td>180</td>
<td></td>
<td>181</td>
<td></td>
</tr>
<tr>
<td>Morbidity, %</td>
<td>11.43</td>
<td>128</td>
<td>8.46*</td>
<td>95</td>
</tr>
<tr>
<td>Days to BRD Break</td>
<td>17.2</td>
<td></td>
<td>17.70</td>
<td></td>
</tr>
<tr>
<td>Mortality and Euthanized, %</td>
<td>1.07</td>
<td>11</td>
<td>1.83</td>
<td>18</td>
</tr>
<tr>
<td>Chronics, %</td>
<td>0.97</td>
<td>10</td>
<td>0.71</td>
<td>7</td>
</tr>
<tr>
<td>Relapse, %</td>
<td>1.25</td>
<td>15</td>
<td>1.04</td>
<td>12</td>
</tr>
<tr>
<td>Removed, %</td>
<td>1.69</td>
<td>18</td>
<td>0.98</td>
<td>10</td>
</tr>
<tr>
<td>Out Weight, lb.</td>
<td>272</td>
<td>1,000</td>
<td>272</td>
<td>1,003</td>
</tr>
<tr>
<td>ADG, lb.</td>
<td>2.17</td>
<td>1,000</td>
<td>2.15</td>
<td>1,003</td>
</tr>
</tbody>
</table>

*P = 0.032

Draxxin is a trademark of Zoetis Inc., its affiliates and/or its licensors. Copyright © 2014 Intervet, Inc., a subsidiary of Merck and Co., Inc. d/b/a Merck Animal Health, 556 Morris Avenue, Summit, NJ 07901. All rights reserved. ZUPCA-117-R
For additional Zuprevo 18% information go to www.zuprevo.com.

**WARNING:** Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

**Note:** Tildipirosin is the nonproprietary name for (11E,13E)-5-dihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-16-ethyl-

**INDICATIONS:** Zuprevo 18% is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef and non-lactating dairy cattle, and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with M. haemolytica, P. multocida, and H. somni.

**USAGE AND ADMINISTRATION:** Inject subcutaneously as a single dose in the neck at a dosage of 4 mg/kg (1 mL/100 lb body weight [BW]). Do not inject more than 10 mL per injection site. Do not puncture the stopper of the respective vial size more than the tested number of punctures, shown in Table 1.

**RESIDUE WARNING:** Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

**PRECAUTIONS:** The effects of Zuprevo 18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond the surgical withdrawal period. This may result in trim loss of edible tissue at slaughter.

**CLINICAL PHARMACOLOGY:** Similar to other macrolides, tildipirosin inhibits essential bacterial protein biosynthesis with selective binding to ribosomal subunits in a bacteriostatic and time-dependent manner. Tildipirosin may be bactericidal against certain isolates of M. haemolytica and P. multocida. The following plasma pharmacokinetic (PK) properties of tildipirosin have been observed after a subcutaneous injection of a dose of 4 mg/kg BW in the neck.

**STORAGE CONDITIONS:** Do not store above 30°C (86°F). Do not freeze. The maximum storage time after first puncture is 28 days or at below 25°C (77°F).

**HIV SUPPRESS:** Zuprevo 18% is supplied in 50, 100 and 250 mL amber glass, sterile, multi-dose vials.

**REFERENCES:**


**BIOMEDICINE:** Tildipirosin has been shown in vitro and in vivo antibacterial activity against the bacteria M. haemolytica, P. multocida, and H. somni; three pathogens associated with BRD.

The minimum inhibitory concentrations (MICs) of tildipirosin against the indicated BRD pathogens were determined using the methods described in the M31-A2 standard of the Clinical and Laboratory Standards Institute (CLSI) and are shown in Table 4.

The MICs of tildipirosin were determined for isolates of M. haemolytica, P. multocida, and H. somni obtained from two BRD field studies. In both studies, tested isolates of M. haemolytica and P. multocida were obtained from nasopharyngeal swabs taken prior to treatment from all study animals. Tested isolates of H. somni were obtained from nasopharyngeal swabs taken prior to treatment from all study animals and from nasopharyngeal swabs taken from saline-treated animals classified as treatment failures.

**Table 4:** Tildipirosin minimum inhibitory concentration (MIC) values* of indicated pathogens isolated from BRD field studies in the U.S.

* The correlation between in vitro susceptibility data and clinical effectiveness is unknown.

**ANTIMICROBIAL DRUG:** 180 mg of tildipirosin/mL.

For subcutaneous injection in beef and non-lactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

**CAUTION:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

**DESCRIPTION:** Zuprevo 18% is a ready-to-use sterile injectable solution containing tildipirosin, a semi-synthetic macrolide antibiotic. Each mL of Zuprevo 18% contains 180 mg of tildipirosin as the free base, 82.5 mg citric acid monohydrate and 400 mg propylene glycol, and water up with citric acid monohydrate added to adjust pH.

**CHEMICAL NOMENCLATURE AND STRUCTURE:** Tildipirosin is the IUPAC name for (11E,13E)-5-dihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-16-ethyl-

In a multi-location field study, calves with naturally occurring BRD were treated with tildipirosin. The treatment success rate of the tildipirosin-treated group was compared to the treatment success rate in the saline-treated control group. A treatment success was defined as a calf not designated as a treatment failure from Day 1 to 13 and with normal attitude, normal respiration, and a rectal temperature of <104°F on Day 14. The treatment success rate was significantly higher (p<0.0003) for the tildipirosin-treated group (229/300, 76%) compared to the saline-treated control group (94/200, 47%). There were no BRD-related deaths in the tildipirosin-treated group compared to a 7% (21/300) BRD-related mortality rate in the saline-treated group.

In another multicenter field study, calves at high risk for developing BRD were administered tildipirosin. The treatment success rate of the tildipirosin-treated group was compared to the treatment success rate in the saline-treated control group. A treatment success was defined as a calf not designated as a treatment failure based on clinical respiratory and attitude scoring and, if necessary, rectal temperature measurement of <104°F through the end of the study (Day 14). The treatment success rate was significantly higher (p<0.0001) for the tildipirosin-treated group (305/386, 79%) compared to the saline-treated group (197/387, 51%). There were three treatment failures in the tildipirosin-treated group compared to the saline-treated group (96/200, 32%). There were no BRD-related deaths in the tildipirosin-treated group compared to a 7% (21/300) BRD-related mortality rate in the saline-treated group.

A separate injection site tolerance study was conducted using Zuprevo 18% administered in 5-month-old cattle as these subcutaneous doses of 4, 12 or 20 mg/kg BW given 7 days apart (1X, 3X, and 5X the labeled dose). Animals remained clinically healthy during the study of the labeled dose. Injection site swelling and inflammation, initially severe in some animals, was observed that persisted to the last day of observation (21 days after injection). No other drug-related lesions were observed macroscopically or microscopically at the labeled dose.

**TIME/CONCENTRATION:**

<table>
<thead>
<tr>
<th>Time (hours)</th>
<th>Concentration (mg/mL)</th>
<th>Plasma (P) concentration (μg/mL)</th>
<th>BF/P Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>1545</td>
<td>895</td>
<td>297</td>
</tr>
<tr>
<td>10</td>
<td>2975</td>
<td>1279</td>
<td>242</td>
</tr>
<tr>
<td>24</td>
<td>3448</td>
<td>1433</td>
<td>136</td>
</tr>
<tr>
<td>72</td>
<td>3489</td>
<td>1712</td>
<td>70.7</td>
</tr>
<tr>
<td>96</td>
<td>1644</td>
<td>2024</td>
<td>60.2</td>
</tr>
<tr>
<td>120</td>
<td>1619</td>
<td>1629</td>
<td>52.3</td>
</tr>
<tr>
<td>240</td>
<td>1937</td>
<td>1416</td>
<td>48.7</td>
</tr>
<tr>
<td>336</td>
<td>1225</td>
<td>1682</td>
<td>26.1</td>
</tr>
<tr>
<td>504</td>
<td>935</td>
<td>1032</td>
<td>16.8</td>
</tr>
</tbody>
</table>

Tildipirosin concentrations in bovine fluid collected in vivo from non-anesthetized cattle reflect the bacterial exposure to drug concentrations at the site of action.

**DISCLAIMER:** The information provided herein is intended for use by veterinarians only. For additional information go to www.zuprevo.com.